OncoCyte Spins Off From BioTime
OncoCyte has spun off as a publicly traded company from BioTime and has begun trading on the NYSE MKT under the symbol OCX.
LifeMap, Lab7 Partner to Provide Integrated NGS Analysis Solution
Their combined offering will provide customers with a single solution for managing lab operations and performing sequence analysis and mutation identification.
Wistar Institute, OncoCyte Expand Lung Cancer Dx Collaboration
The partners will further develop a non-invasive, blood-based test for the early detection of lung cancer.
The researchers are working on an electronic genetic counseling platform that will be in later versions of the app.
OncoCyte, Abcodia Collaborate on Breast Cancer Dx
NEW YORK (GenomeWeb) – OncoCyte and Abcodia today announced they will collaborate on the development of OncoCyte's gene expression-based diagnostic test for the early detection of breast cancer.
May 27, 2014
OncoCyte, Cornell Collaborate on Lung Cancer Dx
Apr 23, 2013
Appistry, LifeMap Partner on NGS Data Analysis
Nov 20, 2012
LifeMap to Offer ProSpec-Tany TechnoGene Products
Apr 20, 2012
BioTime, LifeMap Acquiring XenneX
Nov 29, 2010
BioTime, CIRM Reach Agreement on Stem Cell Lines
Jul 14, 2009